Safety of L-proline as a stabilizer for immunoglobulin products

Expert Review of Clinical Immunology

Volumn 8, Issue 2, 2012, Pages 169-178

  Hagan, John B ^a   Wasserman, Richard L ^b   Baggish, Jeffrey S ^c   Spycher, Martin O ^d   Berger, Melvin ^c   Shashi, Vandana ^e   Lohrmann, Emanuel ^d   Sullivan, Kathleen E ^f  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CSL Behring LLC   (United States)

^d CSL Behring AG   (Switzerland)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

22q11.2 deletion syndrome; hyperprolinemia; intravenous immunoglobulin; pharmacokinetics; proline; proline metabolism; safety; subcutaneous immunoglobulin

Indexed keywords

BILIRUBIN; COLLAGEN; GLYCINE; HUMAN IMMUNOGLOBULIN; IMINO ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROLINE; PROLINE DEHYDROGENASE; PYRROLINE 5 CARBOXYLATE DEHYDROGENASE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ASEPTIC MENINGITIS; BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; CELL DIFFERENTIATION; CHROMOSOME DELETION 22Q11; DIETARY INTAKE; DIGEORGE SYNDROME; DIMERIZATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; ENZYME ACTIVITY; ETHNICITY; EXTRACELLULAR SPACE; FATIGUE; FEVER; FRAGMENTATION REACTION; FREEZING; HEADACHE; HEMORRHOID; HUMAN; HYDROPHOBICITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INJECTION SITE REACTION; INTRACELLULAR SPACE; KIDNEY TUBULE ABSORPTION; LOW DRUG DOSE; LYMPHOCYTOPOIESIS; MAXIMUM PLASMA CONCENTRATION; MAZE TEST; MUCOCUTANEOUS LYMPH NODE SYNDROME; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PAIN; PH; PROTEIN PURIFICATION; RECOMMENDED DRUG DOSE; REVIEW; ROOM TEMPERATURE; SHELF LIFE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STORAGE TEMPERATURE; SYNAPTIC TRANSMISSION; T LYMPHOCYTE; VOMITING; WORKING MEMORY;

ANIMALS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; DRUG STABILITY; DRUG TOXICITY; EXCIPIENTS; GENETIC DISEASES, INBORN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; PROLINE;

EID: 84856619473     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.97     Document Type: Review

References (70)

1. Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev. Clin. Immunol. 7(3), 301-316 (2011).
2. Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin. Exp. Immunol. 164(Suppl. 2), 16-19 (2011).
3. Krane SM. The importance of proline residues in the structure, stability and susceptibility to proteolytic degradation of collagens. Amino Acids 35(4), 703-710 (2008).
4. Wu G. Amino acids: metabolism, functions, and nutrition. Amino Acids 37(1), 1-17 (2009).
5. Tomlinson C, Rafii M, Sgro M, Ball RO, Pencharz P. Arginine is synthesized from proline, not glutamate, in enterally fed human preterm neonates. Pediatr. Res. 69(1), 46-50 (2011).
6. Wu A. Tietz Clinical Guide to Laboratory Tests (4th Edition). Saunders, PA, USA (2006).
7. Voet D, Voet JG. Biochemistry (2nd Edition). John Wiley & Sons, Inc., NJ, USA (1995).
8. Cohen SM, Nadler JV. Proline-induced potentiation of glutamate transmission. Brain Res. 761(2), 271-282 (1997). (Pubitemid 27305987)
9. Krishnan N, Dickman MB, Becker DF. Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radic. Biol. Med. 44(4), 671-681 (2008). (Pubitemid 351172717)
10. Washington JM, Rathjen J, Felquer F, et al. l-proline induces differentiation of ES cells: a novel role for an amino acid in the regulation of pluripotent cells in culture. Am. J. Physiol. Cell Physiol. 298(5), C982-C992 (2010).
11. Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J. Infus. Nurs. 28(6), 366-374 (2005). (Pubitemid 41720695)
12. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev. 58(5-6), 686-706 (2006). (Pubitemid 44255853)
13. Kroez M, Kanzy EJ, Gronski P, Dickneite G. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 31(4), 277-286 (2003). (Pubitemid 37414923)
14. Berger M. L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use. Immunotherapy 3(2), 163-176 (2011).
15. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human g-globulin. Vox Sang. 7, 157-174 (1962).
16. Bleeker WK, Agterberg J, Rigter G, van Rooijen N, Bakker JC. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin. Exp. Immunol. 77(3), 338-344 (1989). (Pubitemid 19234379)
17. Andresen I, Kovarik JM, Spycher M, Bolli R. Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations. J. Clin. Pharmacol. 40(7), 722-730 (2000).
18. Szenczi A, Kardos J, Medgyesi GA, Zavodszky P. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution. Biologicals 34(1), 5-14 (2006).
19. Bolli R, Woodtli K, Bartschi M, Hofferer L, Lerch P. l-proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals 38(1), 150-157 (2010).
20. Maeder W, Lieby P, Sebald A, Spycher M, Pedrussio R, Bolli R. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals 39(1), 43-49 (2011).
21. Cramer M, Frei R, Sebald A, Mazzoletti P, Maeder W. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with l-proline. Vox Sang. 96(3), 219-225 (2009).
22. Cramer M, Frei R, Sebald A, Mazzoletti P, Maeder W. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with l-proline. Vox Sang. 96(3), 219-225 (2009).
23. Hizentra (Immune Globulin Subcutaneous (Human), 20% Liquid). Full prescribing information, CSL Behring, LLC, IL, USA (2011).
24. Privigen (Immune Globulin Intravenous (Human), 10% Liquid). Full prescribing information, CSL Behring, LLC, IL, USA (2011).
25. Privigen (human normal immunoglobulin). EPAR-product information, CSL Behring GmbH, Marburg, Germany (2011).
26. Hizentra (human normal immunoglobulin [SCIg]). EPAR-Product Information CSL Behring GmbH Marburg Germany (2011).
27. Phang J, Chien-an A, Valle D. Disorders of proline and hydroxyproline metabolism. In: Disorders of Proline and Hydroxyproline Metabolism (7th Edition). Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A (Eds). McGraw-Hill, NY, USA (2007).
28. Goodman BK, Rutberg J, Lin WW, Pulver AE, Thomas GH. Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. J. Inherit. Metab. Dis. 23(8), 847-848 (2000). (Pubitemid 32036721)
29. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 370(9596), 1443-1452 (2007). (Pubitemid 47576169)
30. McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore). 90(1), 1-18 (2011).
31. Shprintzen RJ. Velo-cardio-facial syndrome: 30 years of study. Dev. Disabil. Res. Rev. 14(1), 3-10 (2008). (Pubitemid 351716517)
32. Botto LD, May K, Fernhoff PM, et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112(1 Pt 1), 101-107 (2003). (Pubitemid 36792936)
33. Veerapandiyan A, Abdul-Rahman OA, Adam MP, et al. Chromosome 22q11.2 deletion syndrome in African-American patients: a diagnostic challenge. Am. J. Med. Genet. A. 155(9), 2186-2195 (2011).
34. Raux G, Bumsel E, Hecketsweiler B, et al. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum. Mol. Genet. 16(1), 83-91 (2007). (Pubitemid 46152546)
35. Lewandowski KE, Shashi V, Berry PM, Kwapil TR. Schizophrenic-like neurocognitive deficits in children and adolescents with 22q11 deletion syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(1), 27-36 (2007). (Pubitemid 46127391)
36. McDonald-McGinn DM, LaRossa D, Goldmuntz E, et al. The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patients. Genet. Test. 1(2), 99-108 (1997). (Pubitemid 127528777)
37. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455(7210), 237-241 (2008).
38. Sullivan KE, Jawad AF, Randall P, et al. Lack of correlation between impaired T cell production, immunodeficiency, and other phenotypic features in chromosome 22q11.2 deletion syndromes. Clin. Immunol. Immunopathol. 86(2), 141-146 (1998). (Pubitemid 28081550)
39. Sullivan KE, McDonald-McGinn D, Driscoll DA, Emanuel BS, Zackai EH, Jawad AF. Longitudinal analysis of lymphocyte function and numbers in the first year of life in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/ velocardiofacial syndrome). Clin. Diagn. Lab. Immunol. 6(6), 906-911 (1999). (Pubitemid 29529986)
40. Ballow M, Notarangelo L, Grimbacher B, et al. Immunodeficiencies. Clin. Exp. Immunol. 158(Suppl. 1), 14-22 (2009).
41. Sullivan K. Hypogammaglobulinemia in DiGeorge syndrome: a registry approach. Presented at: Clinical Immunology Society. Chicago, IL, USA, 19-22 May 2011.
42. Campbell HD, Webb GC, Young IG. A human homologue of the Drosophila melanogaster sluggish-A (proline oxidase) gene maps to 22q11.2, and is a candidate gene for Type-1 hyperprolinaemia. Hum. Genet. 101(1), 69-74 (1997). (Pubitemid 28014645)
43. Delwing D, Bavaresco CS, Wannmacher CM, Wajner M, Dutra-Filho CS, Wyse AT. Proline induces oxidative stress in cerebral cortex of rats. Int. J. Dev. Neurosci. 21(2), 105-110 (2003). (Pubitemid 36287120)
44. Ferreira AG, Lima DD, Delwing D, et al. Proline impairs energy metabolism in cerebral cortex of young rats. Metab. Brain Dis. 25(2), 161-168 (2010).
45. Bavaresco CS, Streck EL, Netto CA, Wyse AT. Chronic hyperprolinemia provokes a memory deficit in the Morris water maze task. Metab. Brain Dis. 20(1), 73-80 (2005). (Pubitemid 40685327)
46. Moreira JC, Wannmacher CM, Costa SM, Wajner M. Effect of proline administration on rat behavior in aversive and nonaversive tasks. Pharmacol. Biochem. Behav. 32(4), 885-890 (1989). (Pubitemid 19210271)
47. Shanti ND, Shashikumar KC, Desai PV. Influence of proline on rat brain activities of alanine aminotransferase, aspartate aminotransferase and acid phosphatase. Neurochem. Res. 29(12), 2197-2206 (2004). (Pubitemid 40036891)
48. Delwing D, Bavaresco CS, Chiarani F, et al. In vivo and in vitro effects of proline on some parameters of oxidative stress in rat brain. Brain Res. 991(1-2), 180-186 (2003). (Pubitemid 37297947)
49. Delwing D, Chiarani F, Bavaresco CS, et al. Protective effect of antioxidants on brain oxidative damage caused by proline administration. Neurosci. Res. 52(1), 69-74 (2005). (Pubitemid 40461873)
50. Adibi SA, Gray SJ, Menden E. The kinetics of amino acid absorption and alteration of plasma composition of free amino acids after intestinal perfusion of amino acid mixtures. Am. J. Clin. Nutr. 20(1), 24-33 (1967).
51. Jaksic T, Wagner DA, Burke JF, Young VR. Plasma proline kinetics and the regulation of proline synthesis in man. Metabolism 36(11), 1040-1046 (1987). (Pubitemid 18025030)
52. Maher TJ, Glaeser BS, Wurtman RJ. Diurnal variations in plasma concentrations of basic and neutral amino acids and in red cell concentrations of aspartate and glutamate: effects of dietary protein intake. Am. J. Clin. Nutr. 39(5), 722-729 (1984). (Pubitemid 14101227)
53. Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J. Clin. Immunol. 29(1), 137-144 (2009).
54. Hayasaka S, Saito T, Nakajima H, Takahashi O, Mizuno K, Tada K. Clinical trials of vitamin B6 and proline supplementation for gyrate atrophy of the choroid and retina. Br. J. Ophthalmol. 69(4), 283-290 (1985). (Pubitemid 15095770)
55. Scriver CR, Efron ML, Schafer IA. Renal tubular transport of proline, hydroxyproline, and glycine in health and in familial hyperprolinemia. J. Clin. Invest. 43, 374-385 (1964).
56. Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology 14(4), 227-236 (2009).
57. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J. Clin. Immunol. 30(5), 734-745 (2010).
58. Jacquet H, Berthelot J, Bonnemains C, et al. The severe form of Type 1 hyperprolinaemia results from homozygous inactivation of the PRODH gene. J. Med. Genet. 40(1), e7 (2003).
59. Afenjar A, Moutard ML, Doummar D, et al. Early neurological phenotype in 4 children with biallelic PRODH mutations. Brain Dev. 29(9), 547-552 (2007). (Pubitemid 47332140)
60. Bender HU, Almashanu S, Steel G, et al. Functional consequences of PRODH missense mutations. Am. J. Hum. Genet. 76(3), 409-420 (2005). (Pubitemid 40250521)
61. Clelland CL, Read LL, Baraldi AN, et al. Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome. Schizophr. Res. 131(1-3), 139-145 (2011).
62. Jacquet H, Demily C, Houy E, et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol. Psychiatr. 10(5), 479-485 (2005). (Pubitemid 40646436)
63. Jacquet H, Rapoport JL, Hecketsweiler B, et al. Hyperprolinemia is not associated with childhood onset schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B(2), 192 (2006). (Pubitemid 43214796)
64. Williams HJ, Williams N, Spurlock G, et al. Detailed analysis of PRODH and PsPRODH reveals no association with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 120B(1), 42-46 (2003). (Pubitemid 37059378)
65. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol. 221(6), 1629-1639 (1971).
66. Takanaga H, Tokuda N, Ohtsuki S, Hosoya K, Terasaki T. ATA2 is predominantly expressed as system A at the blood-brain barrier and acts as brain-to-blood efflux transport for l-proline. Mol. Pharmacol. 61(6), 1289-1296 (2002). (Pubitemid 34575738)
67. Humbertclaude V, Rivier F, Roubertie A, et al. Is hyperprolinemia Type 1 actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. J. Child Neurol. 16(8), 622-623 (2001). (Pubitemid 32798893)
68. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J. Clin. Immunol. 27(5), 497-502 (2007). (Pubitemid 47319256)
69. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). Food and Nutrition Board. www.nap.edu
70. US population clock 2011. http://factfinder2.census.gov/faces/nav/jsf/ pages/index.xhtml